JP2018501299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501299A5 JP2018501299A5 JP2017543308A JP2017543308A JP2018501299A5 JP 2018501299 A5 JP2018501299 A5 JP 2018501299A5 JP 2017543308 A JP2017543308 A JP 2017543308A JP 2017543308 A JP2017543308 A JP 2017543308A JP 2018501299 A5 JP2018501299 A5 JP 2018501299A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- deuterium
- compound
- acceptable salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 188
- 229910052805 deuterium Inorganic materials 0.000 claims description 187
- 150000001875 compounds Chemical class 0.000 claims description 186
- 239000008194 pharmaceutical composition Substances 0.000 claims description 153
- 150000003839 salts Chemical class 0.000 claims description 142
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 claims description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 52
- 229960003299 ketamine Drugs 0.000 claims description 52
- 208000002193 Pain Diseases 0.000 claims description 43
- 230000002401 inhibitory effect Effects 0.000 claims description 40
- 230000001508 neuroinhibitory effect Effects 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 210000005036 nerve Anatomy 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 239000007916 tablet composition Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 21
- 238000013270 controlled release Methods 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 17
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 230000007135 neurotoxicity Effects 0.000 claims description 7
- 231100000228 neurotoxicity Toxicity 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- 208000009205 Tinnitus Diseases 0.000 claims description 5
- 230000008482 dysregulation Effects 0.000 claims description 5
- 229960004502 levodopa Drugs 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 231100000886 tinnitus Toxicity 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 206010010144 Completed suicide Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 5
- 239000007935 oral tablet Substances 0.000 claims 2
- 229940096978 oral tablet Drugs 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 51
- 0 *C(C(*)(*)C(*)=C(*)C1=O)C1(c(c(*)c(*)c(*)c1*)c1Cl)N(*)* Chemical compound *C(C(*)(*)C(*)=C(*)C1=O)C1(c(c(*)c(*)c(*)c1*)c1Cl)N(*)* 0.000 description 14
- 239000006186 oral dosage form Substances 0.000 description 10
- 208000020925 Bipolar disease Diseases 0.000 description 7
- 208000004296 neuralgia Diseases 0.000 description 7
- 208000021722 neuropathic pain Diseases 0.000 description 7
- 208000008035 Back Pain Diseases 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 6
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000399 orthopedic effect Effects 0.000 description 6
- 239000007894 caplet Substances 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010049714 Abdominal migraine Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010005063 Bladder pain Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- 206010070308 Refractory cancer Diseases 0.000 description 3
- 208000008765 Sciatica Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010042458 Suicidal ideation Diseases 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000006197 inhalational dosage form Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNSMPSPTFDIWRQ-GSVOUGTGSA-N (2r)-4-amino-2-(methylamino)-4-oxobutanoic acid Chemical compound CN[C@@H](C(O)=O)CC(N)=O LNSMPSPTFDIWRQ-GSVOUGTGSA-N 0.000 description 1
- BEQZHFIKTBVCAU-LBPRGKRZSA-N (2s)-2-amino-2-(2-chlorophenyl)cyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(N)CCCCC1=O BEQZHFIKTBVCAU-LBPRGKRZSA-N 0.000 description 1
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000006137 substance-induced psychosis Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078368A JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462074645P | 2014-11-04 | 2014-11-04 | |
| US62/074,645 | 2014-11-04 | ||
| PCT/US2015/059113 WO2016073653A1 (en) | 2014-11-04 | 2015-11-04 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078368A Division JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501299A JP2018501299A (ja) | 2018-01-18 |
| JP2018501299A5 true JP2018501299A5 (enExample) | 2018-12-13 |
| JP6882180B2 JP6882180B2 (ja) | 2021-06-02 |
Family
ID=55909773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543308A Active JP6882180B2 (ja) | 2014-11-04 | 2015-11-04 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
| JP2021078368A Pending JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078368A Pending JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10252982B2 (enExample) |
| EP (2) | EP4393487A3 (enExample) |
| JP (2) | JP6882180B2 (enExample) |
| KR (1) | KR102604397B1 (enExample) |
| CN (2) | CN115521217A (enExample) |
| AU (1) | AU2015343083B2 (enExample) |
| CA (1) | CA2966737A1 (enExample) |
| DK (1) | DK3215147T3 (enExample) |
| ES (1) | ES2977383T3 (enExample) |
| FI (1) | FI3215147T3 (enExample) |
| HU (1) | HUE066468T2 (enExample) |
| LT (1) | LT3215147T (enExample) |
| PL (1) | PL3215147T3 (enExample) |
| PT (1) | PT3215147T (enExample) |
| RS (1) | RS65411B1 (enExample) |
| RU (1) | RU2771275C2 (enExample) |
| SI (1) | SI3215147T1 (enExample) |
| WO (1) | WO2016073653A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211629T1 (hr) | 2013-09-13 | 2022-02-04 | National University Corporation Chiba University | Primjena r-ketamina i njegove soli kao lijekova |
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| EP3287124B1 (en) | 2014-04-17 | 2022-11-30 | Ketabon GmbH | Oral dosage form of ketamine |
| RU2771275C2 (ru) | 2014-11-04 | 2022-04-29 | Аморса Терапьютикс, Инк. | Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения |
| WO2016186968A1 (en) * | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| CN110035997A (zh) * | 2016-09-16 | 2019-07-19 | 生物制药沃克斯有限公司 | 羟基去甲氯胺酮前药 |
| US20190240184A1 (en) * | 2016-10-27 | 2019-08-08 | National University Corporation Chiba University | Pharmaceutical applications for (s)-norketamine and salts thereof |
| CA3059775A1 (en) | 2017-04-13 | 2018-10-18 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| WO2018234568A2 (en) * | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION |
| EP3532457B1 (en) | 2017-07-31 | 2020-03-18 | Small Pharma Ltd | Crystalline forms of hydroxynorketamine |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| WO2019073408A1 (en) * | 2017-10-10 | 2019-04-18 | Douglas Pharmaceuticals Ltd. | PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| EP3501503A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| CN118453559A (zh) | 2018-02-15 | 2024-08-09 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| CA3099293A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| BR112020023882A2 (pt) | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| US11865088B2 (en) | 2018-10-05 | 2024-01-09 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| CN113939286A (zh) * | 2019-03-25 | 2022-01-14 | 道格拉斯制药有限公司 | 缓释药物制剂 |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| EP3965733A4 (en) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE |
| CN114302721B (zh) * | 2019-08-06 | 2025-07-18 | 加利福尼亚大学董事会 | 聚酮的可规模化制备 |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| WO2021137148A1 (en) * | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| US12268658B2 (en) | 2019-12-30 | 2025-04-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| US12478592B2 (en) | 2019-12-30 | 2025-11-25 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| CA3190204A1 (en) * | 2020-09-24 | 2022-03-31 | Paul William Glue | Extended release pharmaceutical formulation |
| CN114524737B (zh) * | 2020-11-23 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种取代的环己酮类化合物 |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| JP2024515891A (ja) * | 2021-04-30 | 2024-04-10 | プログレッシブ セラピューティクス インコーポレーテッド | 情緒障害の処置のためのケタミン及びカンナビス |
| CN116730853A (zh) * | 2022-03-04 | 2023-09-12 | 上海致根医药科技有限公司 | 新型氨基酮类化合物及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| CA2506615A1 (en) * | 2002-11-18 | 2004-06-03 | Yaupon Therapeutics, Inc. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
| US20100076087A1 (en) * | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| CN101765582A (zh) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| WO2015031410A1 (en) | 2013-08-26 | 2015-03-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| RU2771275C2 (ru) | 2014-11-04 | 2022-04-29 | Аморса Терапьютикс, Инк. | Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения |
-
2015
- 2015-11-04 RU RU2017119222A patent/RU2771275C2/ru active
- 2015-11-04 PL PL15856205.8T patent/PL3215147T3/pl unknown
- 2015-11-04 HU HUE15856205A patent/HUE066468T2/hu unknown
- 2015-11-04 WO PCT/US2015/059113 patent/WO2016073653A1/en not_active Ceased
- 2015-11-04 US US15/524,224 patent/US10252982B2/en active Active
- 2015-11-04 EP EP24159685.7A patent/EP4393487A3/en active Pending
- 2015-11-04 ES ES15856205T patent/ES2977383T3/es active Active
- 2015-11-04 JP JP2017543308A patent/JP6882180B2/ja active Active
- 2015-11-04 SI SI201532004T patent/SI3215147T1/sl unknown
- 2015-11-04 EP EP15856205.8A patent/EP3215147B1/en active Active
- 2015-11-04 RS RS20240383A patent/RS65411B1/sr unknown
- 2015-11-04 CN CN202211196697.5A patent/CN115521217A/zh active Pending
- 2015-11-04 PT PT158562058T patent/PT3215147T/pt unknown
- 2015-11-04 DK DK15856205.8T patent/DK3215147T3/da active
- 2015-11-04 CN CN201580072316.4A patent/CN107106529A/zh active Pending
- 2015-11-04 KR KR1020177015310A patent/KR102604397B1/ko active Active
- 2015-11-04 AU AU2015343083A patent/AU2015343083B2/en active Active
- 2015-11-04 LT LTEPPCT/US2015/059113T patent/LT3215147T/lt unknown
- 2015-11-04 CA CA2966737A patent/CA2966737A1/en active Pending
- 2015-11-04 FI FIEP15856205.8T patent/FI3215147T3/fi active
-
2019
- 2019-02-08 US US16/271,767 patent/US10981859B2/en active Active
-
2021
- 2021-03-09 US US17/196,986 patent/US11603348B2/en active Active
- 2021-05-06 JP JP2021078368A patent/JP2021120389A/ja active Pending
-
2022
- 2022-08-05 US US17/882,046 patent/US11613515B2/en active Active
-
2023
- 2023-02-14 US US18/168,950 patent/US12466783B2/en active Active
-
2025
- 2025-10-13 US US19/356,894 patent/US20260109663A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017119222A (ru) | Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения | |
| US20080089861A1 (en) | Combination therapy for treatment of demyelinating conditions | |
| AU2005215775B2 (en) | Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions | |
| CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
| CN101247795B (zh) | 用于治疗与中枢神经系统（cns）相关疾病的方法和组合物 | |
| US20050245460A1 (en) | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders | |
| US20090253728A1 (en) | Methods and Compositions for Treating Nociceptive Pain | |
| HRP20120317T1 (hr) | Spojevi morfinana | |
| WO2014177676A1 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| CN101448502A (zh) | 用于治疗慢性疼痛的特麦角脲/丙麦角脲 | |
| JP2022535894A5 (enExample) | ||
| MX2010014223A (es) | Composiciones pediatricas para el tratamiento de esclerosis multiple. | |
| JP2008531594A5 (enExample) | ||
| IL292725A (en) | Benzazepines are combined for the treatment of Tourette syndrome | |
| MX2008012729A (es) | Inhibidores de renina para el tratamiento de hipertension. | |
| WO2020207344A1 (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| Chabukswar et al. | A REVIEW ON APPLICATIONS OF DEXMEDETOMIDINE (BXCL501) IN CNS DISORDERS | |
| NZ788970A (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| CN111050800A (zh) | 血清素3受体激动剂对疼痛的治疗 | |
| Fabiano et al. | P. 7. a. 001 Agomelatine efficacy on major sleep disturbances in Smith-Magenis syndrome: an exploratory, open study in children | |
| NZ788970B2 (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| EP0626849A1 (en) | Brofaromine as an agent for treating post-traumatic stress | |
| AU2024204318A1 (en) | Treatment of Post-Traumatic Syndrome Disorder | |
| KR20070017136A (ko) | 정신과적 질환의 치료를 위한 ｎｍｄａ 수용체 길항제와항우울제 ｍａｏ 억제제 또는 ｇａｄｐｈ 억제제의 조합물 |